GLP-1 and Glucagon Receptor Agonist Mazdutide Improves Markers of Metabolic Function in Adults with Overweight or Obesity
doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review
For some patients, injecting the medication at a different time of day can make a difference
INS-1 cells were cultured in different concentrations of cholesterol (0, 1, 2.5, 5, or 10 mM) for 24 h
Following the FDAs ruling in September 2023, injectable BPC 157 is no longer available from compounding pharmacies due to concerns regarding its adverse risk profile
